{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:22:31Z","timestamp":1760548951674},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2010,5,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Preoperative chemoradiotherapy is a primary treatment option for patients with resectable esophageal cancer. Combination regimens using newer agents may improve patient outcomes. This multicenter community-based phase I\/II trial examined a modern triplet regimen comprised of oxaliplatin, docetaxel, and capecitabine (ODC) combined with radiation therapy (RT). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> The primary end point was the pathologic complete response (pCR) rate. Eligibility criteria included resectable stage I to III cancer of the mid-\/distal-esophagus or gastroesophageal junction, measurable disease, and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. Treatment included oxaliplatin 40 mg\/m<jats:sup>2<\/jats:sup>, docetaxel 20 mg\/m<jats:sup>2<\/jats:sup> (intravenous, weekly \u00d7 5); capecitabine 1,000 mg\/m<jats:sup>2<\/jats:sup> orally twice daily on days 1 to 7, 15 to 21, and 29 to 35; and concurrent RT (45 Gy). Resection was performed during weeks 9 to 12. ODC and RT safety was determined in a phase I portion (n = 10) preceding phase II. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Fifty-nine patients were enrolled (September 2005 to February 2008; phase I\/cohort 1, 10 patients; phase I\/cohort 2\/phase II, 49 patients). Baseline characteristics included median age of 63 years; 84% male; ECOG PS 0 and 1, 51% and 49%, respectively; adenocarcinoma and squamous cell, 69% and 18%, respectively; stage I, II, and III, 12%, 41%, and 45%, respectively. Phase I revealed no dose-limiting toxicity. Responses: pCR rate, 49%; objective response rate, 61% (24 complete and six partial responses); stable disease, 6%; and progressive disease, 2%. Sixty-nine percent of patients underwent surgery. Survival: median follow-up, 116 weeks; median disease-free survival (DFS) and overall survival (OS) were 16.3 and 24.1 months, respectively. Two-year DFS and OS were 45.1% and 52.2%, respectively. Most common (\u2265 5%) grade 3 to 4 nonhematologic toxicities were anorexia (20%), dehydration (16%), diarrhea (8%), dysphagia (10%), esophagitis (20%), fatigue (12%), hyperglycemia (6%), nausea (16%), pulmonary symptoms (14%), sepsis (6%), and vomiting (16%). All other grade 3 to 4 hematologic and nonhematologic toxicities were uncommon (&lt; 5%). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Preoperative ODC plus RT is active and relatively safe in patients with locoregional esophageal cancer. Importantly, this therapy can be administered within 8 weeks. This regimen warrants additional study in this setting and in combination with newer biologic agents. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2009.24.8773","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T03:55:11Z","timestamp":1269921311000},"page":"2213-2219","source":"Crossref","is-referenced-by-count":30,"title":["Phase I\/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction"],"prefix":"10.1200","volume":"28","author":[{"given":"David R.","family":"Spigel","sequence":"first","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Anthony","family":"Greco","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony A.","family":"Meluch","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassie M.","family":"Lane","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Farley","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Gray","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobby L.","family":"Clark","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[{"name":"From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/CA.2007.0010"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23691"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608153350702"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.305"},{"key":"B5","doi-asserted-by":"crossref","first-page":"181s","DOI":"10.1200\/jco.2006.24.18_suppl.4012","volume":"24","author":"Tepper JE","year":"2006","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200307000-00007"},{"key":"B7","first-page":"84","volume":"5","author":"Meluch AA","year":"1999","journal-title":"Cancer J Sci Am"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hym117"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdi207","volume":"16","author":"Pasini F","year":"2005","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.032"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B13","unstructured":"NCCNEC Panel :  Esophageal Cancer, NCCN Clinical Practice Guidelines in Oncology 2009 Fort Washington, PA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707173370304"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(03)00066-7"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70039-6"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-006-0009-6"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1623"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200102000-00018"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.15501"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.4550"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.15629"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2009.24.8773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:25:08Z","timestamp":1653521108000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2009.24.8773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,1]]},"references-count":22,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010,5,1]]}},"alternative-id":["10.1200\/JCO.2009.24.8773"],"URL":"https:\/\/doi.org\/10.1200\/jco.2009.24.8773","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,1]]}}}